WuXi Manufacturing Facility Passes FDA Inspection
Nov 04, 2013
The CRO/CMO WuXi PharmaTech, reports that its that its small-molecule API and advanced intermediate manufacturing facility of WuXi’s wholly owned subsidiary Shanghai SynTheAll Pharmaceutical (STA) completed a general GMP and pre-approval inspection from FDA with no Form 483 issued.
Source: WuXi PharmaTech
Columnists
Outsourcing
EMA Recommends Suspension of 700 Drugs Tested at GVK Site
EMA Recommends Suspension of 700 Drugs Tested at GVK Site GVK Biosciences argues that EMA’s recommended suspension of 700 drugs is disproportional to reported infractions.
Baxter BioPharma Solutions Joins PBOA
Nelson Patterson has been elected to Pharma & Biopharma Outsourcing Association board.
Fill/Finish Capacity Use for Biologics
There are significant differences between small molecules and biologics fill/finish capacity.
Webcasts
- Enhancing Quality and Process Efficiency Using Continuous Manufacturing Technology for Drug Substance and Drug Product
- Safe and Cost-Effective Capsule Filling for Pre-Clinical and First-in-Man Studies
- Maximizing Roller Compaction Benefits with Proper Excipient Selection
- Developing a Comprehensive Tool Kit for Microbial Identification
